Títulos de anti-HBs tras un programa de vacunación en niños y adolescentes: ¿revacunar?

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Anales De Pediatria

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S1695-4033(01)78646-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• La enfermedad neumocócica en el niño.

  2001cited by this paper
• Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme.

  1999cited by this paper
• Hepatitis B vaccination in high-risk infants: 10-year follow-up.

  1999cited by this paper
• Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy.

  1999cited by this paper
• Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose.

  1999cited by this paper
• Thimerosal in Vaccines—An Interim Report to Clinicians

  1999cited by this paper
• A mathematical model predicting anti‐hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B

  1999cited by this paper
• Twelve‐year follow‐up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma‐derived vaccine without booster doses in children

  1999cited by this paper
• Long‐term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen

  1999cited by this paper
• El título de anticuerpos, la memoria inmunológica y la eficacia protectora de la vacuna frente a Haemophilus influenzae tipo B

  1999cited by this paper
• Hepatitis B Vaccine Administered to Children and Adolescents at Yearly Intervals

  1999cited by this paper
• Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children.

  1999cited by this paper
• Increases in levels of antibody to hepatitis B surface antigen in an immunized population.

  1998cited by this paper
• [Evaluation of the effectiveness nine years after primary immunization with local produced plasma-derived hepatitis B vaccine].

  1998cited by this paper
• Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan.

  1998cited by this paper
• Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen.

  1998cited by this paper
• [Follow-up on hepatitis B immunized neonates born to HBsAg positive mothers].

  1998cited by this paper
• Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine.

  1997cited by this paper
• Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study.

  1997cited by this paper
• High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates

  1997cited by this paper
• Vaccines to prevent viral hepatitis.

  1997cited by this paper
• Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity.

  1997cited by this paper
• Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans.

  1996cited by this paper
• The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Perinatal Hepatitis B Immunization Program.

  1996cited by this paper
• Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.

  1996cited by this paper
• Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen‐carrier children who cleared serum‐ hepatitis B surface antigen

  1996cited by this paper
• Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years.

  1996cited by this paper
• Twelve-year follow-up study of hepatitis B immunization of Senegalese infants.

  1994cited by this paper
• Eficacia a largo plazo de la vacuna recombinante de hepatitis B en recién nacidos

  1993cited by this paper
• Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents.

  1993cited by this paper
• [Demonstration of the interchangeability of 2 types of recombinant anti-hepatitis-B vaccine].

  1993cited by this paper
• Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond.

  1993cited by this paper
• A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates.

  1993cited by this paper
• Nine‐year follow‐up study of a plasma‐derived hepatitis B vaccine in a rural African setting

  1993cited by this paper
• Hepatitis B vaccine

  1992cited by this paper
• Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses.

  1991cited by this paper

• Serologia del virus de l'hepatitis B en infants recentment immigrats

  2011cites this paper
• Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine.

  2008cites this paper